Introduction

Vascular endothelial growth factor (VEGF) plays a key role in tumor angiogenesis and in metastasis spreading. In the last decade, anti-angiogenic therapies targeting the VEGF pathway have revolutionized the treatment of metastatic cancer [1]. They include the anti VEGF monoclonal humanized antibody bevacizumab and tyrosine kinase inhibitors, such as sunitinib, that target especially VEGF receptors (VEGF-R) [2]. Such therapies have significantly improved progression-free survival and overall survival [3-5]. Therefore, sunitinib is now recommended as first-line therapy for patients with metastatic renal cell carcinoma, breast cancer and gastrointestinal stromal tumors [6].

However, anti-VEGF drugs can induce several adverse effects (gastrointestinal disorders, skin toxicity and hypertension) that may require dose reduction or discontinuation in half of the patients. Proteinuria after treatment with bevacizumab is observed in 21% to 63% of patients [7], but renal adverse effects may have been underestimated. Indeed, diagnostic kidney biopsies, which are rarely performed in these patients, have highlighted some cases of immunallergic interstitial nephritis [8], focal segmental glomerulosclerosis [9], acute tubular necrosis [10], and more frequently thrombotic microangiopathy (TMA). These lesions are potentially reversible after drug discontinuation [11-14]. Recently, we included 22 patients in the RARE database (Registry of patients with major kidney side effects during treatment with anti-VEGF drugs) [15]. Analysis of the renal biopsies from these patients indicated the presence of acute or chronic TMA in 21. Specifically, the observed lesions (glomerular foot process foot processes) were reminiscent of the alterations observed in preeclampsia [15]. Indeed, there are clinical and pathophysiological similarities between preeclampsia and the renal side effects of anti-VEGF treatments [21].

During preeclampsia, expression of the soluble form of VEGF-R1 (sFLT-1) increases, whereas VEGF serum level decreases [16]. By binding and neutralizing VEGF, sFLT1 inhibits the VEGF signaling pathway. This leads to disorganization of vascular endothelial (VE) cadherin a key component of endothelial cell-cell junctions [19], and consequently to increased vascular permeability and proteinuria. It has been reported that VEGF-A phosphorylates VEGF-R2 and VE-cadherin, ultimately resulting in disassembly of intercellular junctions and increased permeability of the glomerular slit diaphragm [20].

Abstract

Background: VEGF is involved in cancer development by stimulating neo-angiogenesis and tumor proliferation. Anti-angiogenic therapies, especially tyrosine kinase inhibitors such as sunitinib, have significantly improved cancer prognosis. Nevertheless, renal side effects, such as proteinuria and thrombotic microangiopathy, have been reported. The underlying physiopathological mechanisms remain unclear, but animal models and clinical similarities with preeclampsia suggest that such therapies affect the function of the endothelial and epithelial layers of the glomerular basement membrane, with activation of the endothelin signaling network and loss of glomerular slit diaphragm integrity. The aim of this in vitro study was to determine sunitinib effects on normal podocytes and glomerular endothelial cells.

Methods: The glomerular microvascular endothelial (GMVEC) and human glomerular visceral epithelial (hGVE) cell lines were incubated with various doses of sunitinib. The MTT Cell Proliferation Assay was used to assess cell proliferation. Expression of nephrin (a major slit diaphragm protein) and endothelin was evaluated by immunofluorescence or western blotting assays.

Results: Sunitinib inhibited GMVEC and hGVE cell proliferation in a dose-dependent manner. In GMVEC cells, endothelin transcription and secretion were increased after incubation with sunitinib. Conversely, in hGVE cells, sunitinib did not affect nephrin expression. However, conditioned medium from GMVEC cells incubated with sunitinib modified nephrin expression when added to the culture medium of hGVE cells. This effect was inhibited by pre-incubating hGVE cells with an endothelin inhibitor.

Conclusion: This study suggests an indirect toxicity of sunitinib on podocytes through endothelin.

Therefore, sunitinib-induced renal side effects could be controlled with endothelin inhibitors.

Research Article

Anti-VEGF Therapy Induces Proteinuria through Endothelial Disorganization Leading to Nephrin Decrease in Podocytes

Moreover, histological analysis of kidney biopsies from patients with preeclampsia revealed the presence of TMA, with reduced formation of endothelial fenestrae. In mice, injection of sFLT-1 induces a “preeclampsia-like syndrome” with acute hypertension, edema, TMA histological lesions and reduction in nephrin expression [14]. In kidney biopsies from patients treated with anti-VEGF agents, VEGF, synaptopodin and nephrin expression levels are decreased [15], whereas the endothelin signaling system, which stimulates VEGF production [22], is activated [23,24]. Similarly, in preeclampsia, expression of nephrin and synaptopodin is reduced [25]. Loss of nephrin could be due to shedding from the cell surface through endothelin-1 release by endothelial glomerular cells [26].

These studies suggest that the proteinuria induced by anti-VEGF drugs is a consequence of the dysregulation of the slit diaphragm, leading to endothelial and epithelial cell dysfunction. Therefore, the aim of this study was to determine the in vitro effects of sunitinib on normal podocytes and glomerular endothelial cells. Cell-cell interactions in cells incubated with sunitinib were studied to test the hypothesis of endothelin-1 (ET-1) implication, as described in preeclampsia.

Materials and Methods

Cell lines and cell culture methods

The human glomerular visceral epithelial cell line hGVE (i.e., podocytes) was generously given by Pr. Rondeau (INSERM U702, Paris, France) [27]. Cells were cultured in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12, Gibco®, Carlsbad, USA) with 5% fetal bovine serum (FBS) (PAA Laboratories®, Pasching, Austria), 1% Penicillin-Streptomycin solution (10000 U/mL penicillin + 10000 µg/mL streptomycin, Gibco®) and in extenso 1% of 100X Insulin-Transferrin-Selenium-X Supplement (Gibco®). Cells were cultured in 25cm² or 75cm² tissue culture flasks.

The commercial glomerular microvascular endothelial cell line (GMVEC) (ACBR1 128 – CellsSystems®) was isolated from normal human renal cortex. Cells were cultured in EGM™ (Lonza®) and then proteins were extracted with cold lysis buffer (20mM Tris-HCl, 375mM KCl, 15mM MgCl₂, 50mM DTT) (Promega® M531A), 0.5µL of 10mM dNTP mix (Promega® U151B), 1µL of 500µg/mL Random Primers (Promega® C118A), 0.2µL of 40µU/mL RNAsin Plus RNase Inhibitor (Promega® N261A) and 0.3µL of 200U/µL M-MLV Reverse Transcriptase® (M170A, Promega®, Madison, USA). RT was performed in triplicate in a PTC 200-Peltier Thermal Cycler (MJ Research), according to the manufacturer’s instructions. Complementary DNA samples were stored at -20°C.

Sequence-specific oligonucleotide primers: Primers were purchased from Eurogentec® (Seraing, Belgium) or Sigma®, GAPDH: forward, 5’-CTGACCTCAACAGCAGACC-3’ and reverse, 5’-TAGGAAAATTCGTTTCATACC-3’; ET-1: forward, 5’TCTCTGCTGTTTGTGCTG-3’ and reverse, 5’GAGCTCAAAGCCTAAGACTG-3’; VEcadherin: forward, 5’-ACCCCA CAGGAAAAGAATACT-3’ and reverse, 5’ACACACTTGTGCTG-3’; TMA histological lesions and reduction in nephrin FLUO-star Omega spectrophotometer (BMG Labtech®, Offenbourg, Germany). Experiments were done in triplicate.

RNA purification

RNA was extracted using the RNeasy® Mini Kit according to the manufacturer’s protocol (Qiagen® Venlo, Netherlands). RNA concentration was determined in duplicate using a Nano Drop ND-1000 spectrophotometer (Thermo Scientific®, Wilmington, USA).

Quantitative polymerase chain reaction (qPCR)

Reverse transcription (RT): For each sample, 2µg of RNA were mixed with 7µL reaction mix and RNase-free water to a final volume of 25µL. The reaction mix contained 5µL 5X reaction buffer (250mM Tris-HCl, 375mM KCl, 15mM MgCl₂, 50mM DTT) (Promega® M531A), 0.5µL of 10mM dNTP mix (Promega® U151B), 1µL of 500µg/mL Random Primers (Promega® C118A), 0.2µL of 40µU/mL RNAsin Plus RNase Inhibitor (Promega® N261A) and 0.3µL of 200U/µL M-MLV Reverse Transcriptase® (M170A, Promega®, Madison, USA). RT was performed in triplicate in a PTC 200-Peltier Thermal Cycler (MJ Research), according to the manufacturer’s instructions. Complementary DNA samples were stored at -20°C.

Relative quantification by real-time PCR was performed using the Applied 7900HT Fast Real-Time PCR System (Applied Biosystems®) and the Power SYBR® Green PCR Master Mix (Applied Biosystems®, Foster City, USA). Experiments were done in triplicate. Double-distilled water blanks and samples reverse transcribed without reverse transcriptase served as negative controls for each run.

Western blot analysis

Protein extraction: Cells were rinsed twice with phosphate-buffered saline (PBS: 10mM sodium phosphate, pH 7.5, 0.9% saline), and then proteins were extracted with cold lysis buffer (20mM Tris-HCl pH 7.5 (Sigma Aldrich®, Saint-Louis, USA), 100mM NaCl, 5mM MgCl₂, 0.5mM diithiothreitol, 20mM β–glycerocephosphate, 0.2% Nonidet-P40, 10% glycerol, 10µL/mL Protease Inhibitor Cocktail Set IV® (Calbiochem®, Gibbstown, USA) and 200µL/mL Phosphatase Inhibitor Cocktail Set III® (Calbiochem®, Gibbstown, USA).

Extractions were performed at 4°C for 30min and then samples were centrifuged at 13,000rpm for 30min.

Protein concentration: The protein concentration of each sample was determined using the Bradford Reagent B6916 (Sigma-Aldrich®) and bovine serum albumin (BSA) (Sigma®) as protein standard.
Absorbance was determined by spectrophotometry on a Jenway 6051 Colorimeter (Jenway®, Felsted, UK).

Enzyme-linked immunosorbent assay (ELISA)
The human ET-1 QuantiGlo ELISA kit (R&D Systems®, Abingdon, United Kingdom) was used according to the manufacturer’s specifications. ET-1 concentration in aliquots of supernatants from GMVEC cells incubated or not with sunitinib was measured in duplicate. Results were analyzed with the Ascent Software, Multiskan RC (Thermo LabSystems®, Cergy-Pontoise, France), at the wavelength of 450nm.

Immunocytochemistry

Cells were plated on eight-well Labtech® chamber slides (30,000 cells/well). The following day, treatment was initiated. At the end of the treatment, cells were rinsed with PBS and fixed in 3.65% formaldehyde (36.7% Formol, Sigma-Aldrich®). Cells were then incubated with 10% hydrogen peroxide for 5min, followed, if needed, by permeabilization by incubation in 0.1% Triton X-100 in PBS for 3min. Blocking was performed with 3% BSA/PBS for 1h, followed by rinses with 1% BSA/ PBS for 10min. Cells were stained with primary antibodies diluted in PBS for 1h30. Commercially available kits were used for secondary antibodies (Dual Link System-HRP, Dako®). Antibody reactions were revealed with 3,3-diaminobenzidine (Dako®, Glostrup, Denmark), followed by counterstaining with 0.5X hematoxylin. Slides were mounted with Faramount Aqueous Mounting Medium (Dako®, Denmark) and stored at room temperature. Images were acquired with a Leica® DFC 295 microscope.

Statistical analysis

Results are representative of at least three independent experiments performed in triplicate, unless otherwise mentioned. Results are expressed as the mean ± standard deviation (SD). Statistical analysis of the data was performed using the Student’s t-test for independent variables and the R software (Bell Laboratories, USA). Differences were considered significant when p<0.05.

Results

Sunitinib reduces proliferation of hGVE and GMVEC cells

To test the in vitro effects of sunitinib on glomerular epithelial and endothelial cells, hGVE and GMVEC cells were plated in 96-well plates (2000 cells/well) and incubated with different concentrations (0.15µM, 1.5µM, and 5µM) of sunitinib or vehicle alone (DMSO; control cells). Cell proliferation/viability was then assessed with the MTT Cell Proliferation Assay at 24h (D1), 48h (D2), 72h (D3) and 96h (D4) after addition of sunitinib. Compared with control cells, sunitinib reduced proliferation/viability of both hGVE and GMVEC cells in a dose-dependent manner (Figure 1). The 5µM concentration was too toxic, leading to a high rate of cell mortality (data not shown) and therefore was not used in the subsequent experiments.

Sunitinib does not affect slit diaphragm protein expression in hGVE cells

As nephrin expression is decreased in kidney biopsies from Biomedicals, USA) and cells analyzed with a fluorescence microscope (LEICA® DMRXA, Germany).
patients treated with anti-VEGF agents [15], we evaluated whether sunitinib directly affected nephrin expression in podocytes by western blot analysis of hGVE cells incubated with 0.15µM or 1.5µM sunitinib for 1 to 3 days. Sunitinib did not modify nephrin expression compared with untreated cells (DMSO) at any of the tested concentrations (Figure 2A). Similar results were obtained by immunocytochemistry analysis of hGVE cells incubated with 1.5µM sunitinib (b) or DMSO (a) for 48h (Figure 2B).

Sunitinib does not affect ET-1 and ET receptor type A expression in hGVE cells

As hGVE cells can synthesize ET-1, which regulates the VEGF pathway, and express endothelin receptor type A (ET-RA), we then evaluated whether sunitinib influenced their expression.

ET-RA expression was assessed by western blotting (Figure 3A) and RT-qPCR (Figure 3B) in hGVE cells incubated with sunitinib or DMSO for 24, 48 or 72h. A non-significant time-dependent ET-RA increase was observed in DMSO- and sunitinib-treated cells (Figure 3A). ETRA protein and mRNA expression were not significantly different in DMSO- and sunitinib treated hGVE cells, although huge variations in expression were observed by RT-qPCR analysis.

Similarly, RT-qPCR analysis of ET-1 expression in DMSO- and sunitinib-treated hGVE cells indicated that sunitinib did not affect its expression level (Figure 3C).

Sunitinib affects VE-cadherin organization and ET-1 expression in GMVEC cells

As in kidney biopsies from women with preeclampsia, cell-cell junctions are disturbed in activated glomerular endothelium and this endothelium secretes ET-1, we tested the effect of sunitinib also in GMVEC cells.

Immunofluorescence analysis of GMVEC cells incubated with sunitinib for 24 to 72 hours indicated that sunitinib treatment induced a disorganization of VE-cadherin localization (right panel) compared to DMSO-treated cells (left panel) (Figure 4a). This effect was not due to changes in VE-cadherin expression level because RT-qPCR quantification of VE-cadherin gene expression level indicated that it was not significantly different in treated and untreated cells, whatever the sunitinib concentration (Figure 4b).

Conversely, incubation with 1.5 µM sunitinib induced an increase of ET-1 expression (Figure 5A) and probably secretion in GMVEC cells (Figure 5B) compared with DMSO-treated cells, although the difference was not significant due to the important result variability.

Conditioned medium from sunitinib-treated GMVEC cells affects nephrin expression and localization in hGVE cells

To try to understand the mechanism underlying nephrin expression reduction in kidney biopsies from patients treated with sunitinib, we hypothesized that sunitinib could alter indirectly the expression of slit diaphragm proteins through its effects on glomerular endothelial cells. To test this hypothesis, GMVEC cells were incubated with DMSO, 0.15µM or 1.5µM sunitinib and culture
Figure 3: Effects of sunitinib on endothelin receptor A (ET-RA) (A and B) and endothelin-1 (C) expression in hGVE cells. hGVE were incubated for 24h, 48h or 72h with sunitinib 0.15µM and 1.5µM. Control DMSO. 
A: analysis of Endothelin receptor A (ET-RA) expression evaluated by Western-blotting.

Figure 4: Sunitinib action on GMVEC cell-cell interaction. GMVEC cells were treated by sunitinib 0.15µM or 1.5µM for 1 to 3 days.
(a): disorganization of VE-Cadherin by immunofluorescence after 3 days of treatment by sunitinib 1.5µM (B) compared to DMSO (A). Original magnification x160. (b): VE-Cadherin gene expression by quantitative PCR. Control DMSO.

Figure 5: Treatment by sunitinib increases ET-1 expression and secretion by GMVEC.
A. ET-1 expression by quantitative PCR. GMVEC were treated for 1 to 3 days by sunitinib 0.15µM and 1.5µM. Control DMSO. *: p<0.05 compared to control DMSO.
B. ET-1 secretion by GMVEC in the medium of culture by ELISA. Collection of supernatants of culture of GMVEC after 1, 2 or 3 days of treatment by sunitinib 0.15µM and 1.5µM. Control DMSO.
supernatant (called conditioned medium, CM) was collected after 24h, 48h and 72h. Then, hGVE cells were grown in the presence of the different CM (undiluted) and cell proliferation/viability and slit diaphragm protein expression were assessed.

Analysis of the results of the MTT proliferation assay indicated that cell proliferation/viability was not significantly different in hGVE cells grown in CM from GMVEC cells incubated with sunitinib (CM-Suni) or with DMSO (CM-DMSO) compared with cells grown in normal culture medium (DMEM), excepted after 72h (Figure 6).

Nephrin membrane expression was studied by immunocytochemistry in hGVE cells grown in the presence of CM for 1h, 24h or 48h. After 1h (Figures 7A,C), nephrin extracellular expression (brown staining) was weaker in hGVE cells incubated with CM-Suni (1.5µM) (C) than in cells incubated in CM-DMSO (A). However, after 24h, nephrin expression was stable, in both hGVE cells incubated with CM-DMSO and CM-Suni (1.5µM) (Figures 7B,D). Similar results were obtained by immunofluorescence analysis. Nephrin expression was decreased in hGVE cells incubated with CM-Suni (0.15 and 1.5µM) for 1h (Figures 7F,G) compared with CM-DMSO (Figure 7E). Moreover, in CM-DMSO treated hGVE cells, nephrin showed predominantly a punctuate perinuclear pattern (arrow) (Figure 7E), whereas CM-Suni treatment induced a redistribution of nephrin expression (F and G). Western blot analysis (Figure 7H) confirmed that nephrin expression was reduced in hGVE cells incubated with CM-Suni in comparison with CM-DMSO or DMSO-treated cells. It also showed that the reduction was proportional to the amount of sunitinib used in GMVEC cells. Moreover, actin distribution also was modified in hGVE cells grown in CM-Suni compared with control cells (CM-DMSO) where actin was organized in filaments along the axis (Figure 8).

**ET-1 role in nephrin expression reduction in CM-treated hGVE cells**

As ET-1 was secreted by sunitinib-treated GMVEC cells, we tested whether it was involved in nephrin expression reduction in hGVE cells treated with CM-Suni. To this aim, hGVE cells were pre-incubated with 0.4µM BQ-123 (an ET-RA inhibitor) for 1h before addition of the different CM, as before. Western blotting and immunofluorescence analysis of nephrin membrane expression showed that pre-treatment of hGVE cells with BQ-123 counteracted the effect of CM-Suni on nephrin expression level and cytoplasmic re-distribution (Figure 9; left and right panels, respectively).

**Discussion**

Sunitinib is the most used anti-VEGF drug in oncology since 2005. Like with the other therapies targeting the VEGF pathway, its use is...
analyzed cell proliferation/viability to assess sunitinib cytotoxicity on hGVE cells that are derived from podocytes and GMVEC. First, we assessed the effects of sunitinib on cells of the glomerular filtration barrier. We used endothelial cells to study the role of ET-1 following sunitinib-mediated promotion of its secretion by endothelial cells. Histologically, TMA showed that the ET-1 system in hGVE cells is involved in the development of proteinuria. Conversely, when hGVE cells were cultured in the presence of CM from sunitinib-treated GMVEC cells, nephrin expression was reduced. As several mediators have been reported to affect nephrin expression/localization by activation of the cell cytoskeleton and the extracellular domain of nephrin [34], we investigated actin organization in hGVE cells cultured in the presence of CM from sunitinib-treated GMVEC cells. We confirmed that nephrin expression was reduced. As several mediators have been reported to affect nephrin expression/localization by activation of the cell cytoskeleton and by cleavage of the extracellular domain of nephrin [34], we also investigated actin organization in hGVE cells cultured with CM and found that actin distribution was affected only in cells grown in CM-Suni. We can hypothesize that activation of the cell cytoskeleton modifies nephrin surface expression because total nephrin expression was not altered. Moreover, our findings highlight the role of ET-RA in nephrin decrease and cytoskeleton activation because pre-incubation with an antagonist of this receptor blocked the effects of CM-Suni. The therapeutic potential of endothelin antagonists has already been studied in some renal diseases, such as glomerulosclerosis or diabetic nephropathy [35], and our results suggest that they could be useful also for the renal side effects of anti-angiogenic targeted therapies.

Conclusion

In vitro, sunitinib shows dose-dependent toxicity in GMVEC cells (a human glomerular endothelial cell model) and in hGVE cells (a human podocyte model). At high doses, it inhibits cell proliferation and reduces cell viability. Sunitinib does not directly perturb slit diaphragm protein expression in hGVE cells. Conversely, in GMVEC cells, it stimulates ET-1 production and secretion and leads to VE-cadherin disorganization. Sunitinib effects on slit diaphragm proteins seem to be indirect through the action of GMVEC-released ET-1 on ET-RA in hGVE cells. The blockade of sunitinib-induced modifications by endothelin-receptor inhibitors is a very important result for future clinical practice. Indeed, endothelia inhibitors are available and could represent a therapeutic option for the renal side effects of anti-angiogenic drugs in patients with cancer.

References


